pimobendan has been researched along with Cat Diseases in 13 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
Cat Diseases: Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively." | 9.41 | Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021) |
| "Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure." | 8.82 | Use of pimobendan in the management of heart failure. ( Fuentes, VL, 2004) |
| "To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM)." | 7.80 | Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. ( Ames, MK; Atkins, CE; DeFrancesco, TC; Hodge, TE; Keene, BW; Meurs, KM; Reina-Doreste, Y; Stern, JA; Tou, SP, 2014) |
| "To determine the effect of PO administration of pimobendan on clinical and echocardiographic variables and survival time in cats with heart failure characterized by ventricular systolic dysfunction." | 7.78 | Effect of oral administration of pimobendan in cats with heart failure. ( Achen, SE; Boggess, MM; Drourr, L; Fries, RC; Gordon, SG; Hariu, CD; Miller, MW; Roland, RM; Saunders, AB; Winter, RL, 2012) |
| "The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively." | 5.41 | Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021) |
| "Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure." | 4.82 | Use of pimobendan in the management of heart failure. ( Fuentes, VL, 2004) |
| "Pimobendan is frequently used off-label for treatments of cats with congestive heart failure (CHF)." | 3.96 | Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy. ( DeFrancesco, TC; Keene, BW; Kussin, EZ; Tou, SP; Tropf, MA; Ward, JL, 2020) |
| "To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM)." | 3.80 | Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. ( Ames, MK; Atkins, CE; DeFrancesco, TC; Hodge, TE; Keene, BW; Meurs, KM; Reina-Doreste, Y; Stern, JA; Tou, SP, 2014) |
| "To determine the effect of PO administration of pimobendan on clinical and echocardiographic variables and survival time in cats with heart failure characterized by ventricular systolic dysfunction." | 3.78 | Effect of oral administration of pimobendan in cats with heart failure. ( Achen, SE; Boggess, MM; Drourr, L; Fries, RC; Gordon, SG; Hariu, CD; Miller, MW; Roland, RM; Saunders, AB; Winter, RL, 2012) |
| "To describe the therapeutic use of pimobendan in cats, describe the patient population to which it was administered, document potential side effects and report the clinical course following administration of pimobendan in conjunction with standard heart failure therapy." | 3.77 | Use of pimobendan in 170 cats (2006-2010). ( Aronow, N; Cunningham, SM; Hall, DJ; Laste, NJ; Macgregor, JM; Malakoff, RL; Price, LL; Rush, JE; Williams, J, 2011) |
| " Plasma concentrations of pimobendan and O-demethylpimobendan (ODMP) were measured, and pharmacokinetic parameters were calculated for pimobendan by noncompartmental analysis." | 1.72 | Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus). ( Diao, SM; Gunther-Harrington, CT; Guzman, DS; Hawkins, MG; Knych, HK; Masri, AE; Ozawa, SM, 2022) |
| "Pimobendan was well tolerated in the acute setting in cats with HCM." | 1.62 | Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy. ( Fousse, SL; Oldach, MS; Ontiveros, ES; Stern, JA; Ueda, Y; Visser, LC, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Ozawa, SM | 1 |
| Guzman, DS | 1 |
| Hawkins, MG | 1 |
| Diao, SM | 1 |
| Masri, AE | 1 |
| Gunther-Harrington, CT | 1 |
| Knych, HK | 1 |
| Ward, JL | 1 |
| Kussin, EZ | 1 |
| Tropf, MA | 1 |
| Tou, SP | 2 |
| DeFrancesco, TC | 2 |
| Keene, BW | 2 |
| Kochie, SL | 1 |
| Schober, KE | 2 |
| Rhinehart, J | 1 |
| Winter, RL | 2 |
| Bonagura, JD | 1 |
| Showers, A | 1 |
| Yildez, V | 1 |
| Rush, JE | 2 |
| Luis Fuentes, V | 1 |
| Glaus, T | 1 |
| Summerfield, NJ | 1 |
| Wright, K | 1 |
| Lehmkuhl, L | 1 |
| Wess, G | 1 |
| Sayer, MP | 1 |
| Loureiro, J | 1 |
| MacGregor, J | 1 |
| Mohren, N | 1 |
| Oldach, MS | 1 |
| Ueda, Y | 1 |
| Ontiveros, ES | 1 |
| Fousse, SL | 1 |
| Visser, LC | 1 |
| Stern, JA | 2 |
| Wainberg, S | 1 |
| Reina-Doreste, Y | 1 |
| Atkins, CE | 1 |
| Ames, MK | 1 |
| Hodge, TE | 1 |
| Meurs, KM | 1 |
| White, AJ | 1 |
| Duchaussoy, AC | 1 |
| Day, J | 1 |
| Hughes, D | 1 |
| Macgregor, JM | 1 |
| Laste, NJ | 1 |
| Malakoff, RL | 1 |
| Cunningham, SM | 1 |
| Aronow, N | 1 |
| Hall, DJ | 1 |
| Williams, J | 1 |
| Price, LL | 1 |
| Hambrook, LE | 1 |
| Bennett, PF | 1 |
| Gordon, SG | 1 |
| Saunders, AB | 1 |
| Roland, RM | 1 |
| Drourr, L | 1 |
| Achen, SE | 1 |
| Hariu, CD | 1 |
| Fries, RC | 1 |
| Boggess, MM | 1 |
| Miller, MW | 1 |
| Fuentes, VL | 1 |
1 review available for pimobendan and Cat Diseases
| Article | Year |
|---|---|
Use of pimobendan in the management of heart failure.
Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Heart Failure; Phosphodiesteras | 2004 |
2 trials available for pimobendan and Cat Diseases
| Article | Year |
|---|---|
Effects of pimobendan on left atrial transport function in cats.
Topics: Animals; Atrial Function, Left; Cardiomyopathy, Hypertrophic; Cat Diseases; Cats; Cohort Studies; He | 2021 |
Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study.
Topics: Animals; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; H | 2021 |
10 other studies available for pimobendan and Cat Diseases
| Article | Year |
|---|---|
Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus).
Topics: Administration, Oral; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Half-Life; Male; Pilo | 2022 |
Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Cat Diseases; Cats; Heart Failure; Pyridazines; Retro | 2020 |
Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cat | 2021 |
Use of pimobendan in feline congenital heart failure.
Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Female; Heart Failure; Pyridazines; Tricuspid Valve | 2013 |
Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure.
Topics: Animals; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Case-Control Studies; Cat Diseases; Cats; | 2014 |
End-stage hypertrophic cardiomyopathy in a cat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Atenolol; Benzazepines; C | 2015 |
What Is Your Diagnosis? Dilated cardiomyopathy.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Cat Diseases; Cats; Diuretics; Dobutamine; Fur | 2015 |
Use of pimobendan in 170 cats (2006-2010).
Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Dose-Response Relationship, Drug; Female; Follow-Up | 2011 |
Effect of pimobendan on the clinical outcome and survival of cats with non-taurine responsive dilated cardiomyopathy.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Cat Diseases; Cats; Female; Humans; Male; Pyri | 2012 |
Effect of oral administration of pimobendan in cats with heart failure.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Cat Diseases; Cats; Cohort Studies; Female; Heart | 2012 |